Drug
Infigratinib clinical trials
Also written BGJ398.
Keep track of what changes. Save the infigratinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2020 (7)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 7 |
| 2021 | 3 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 13
QED Therapeutics, a BridgeBio company (5) · Novartis Pharmaceuticals (5) · QED Therapeutics, Inc. (3) · Memorial Sloan Kettering Cancer Center (2) · M.D. Anderson Cancer Center (2) · LianBio LLC (2) · Sameek Roychowdhury (1) · Pfizer (1)
Often tested with
Tested in the same studies.
Encorafenib (1) · Binimetinib (1) · Ribociclib (1) · Buparlisib (1) · Capmatinib (1) · Alpelisib (1) · Imatinib (1) · Tamoxifen (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses infigratinib is read from its arms, and is right about nine times in ten.
Testing it · 30
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationPhase 2QED Therapeutics, a BridgeBio companyNCT05145010Written as Infigratinib
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationPhase 2QED Therapeutics, a BridgeBio companyNCT07393373Written as Infigratinib
- An Interventional Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationPhase 2/3QED Therapeutics, a BridgeBio companyNCT06873035Written as infigratinib 0.128 mg/kg/day
- BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the BladderCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT02657486Written as BGJ398
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaCompletedPhase 3QED Therapeutics, a BridgeBio companyNCT06164951Written as Infigratinib 0.25 mg/kg/day
- Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene MutationsCompletedPhase 2Sameek RoychowdhuryNCT04233567Written as Infigratinib
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast CancerTerminatedPhase 1Jennifer Lee Caswell-JinNCT04504331Written as Infigratinib
- Infigratinib in Recurrent High-Grade Glioma PatientsTerminatedEarly Phase 1Nader SanaiNCT04424966Written as Infigratinib
- Study of Infigratinib in Children With AchondroplasiaCompletedPhase 2QED Therapeutics, a BridgeBio companyNCT04265651Written as Infigratinib 0.016 mg/kg
- Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial CancerTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04228042Written as Infigratinib
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedPhase 2LianBio LLCNCT06206278Written as Infigratinib
- Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/TranslocationsTerminatedPhase 3QED Therapeutics, Inc.NCT03773302Written as BGJ398
- Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsTerminatedPhase 3QED Therapeutics, Inc.NCT04197986Written as Infigratinib
- LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedPhase 2PfizerNCT02159066Written as BGJ398
- Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC TrialWithdrawnPhase 2Emory UniversityNCT05514912Written as Infigratinib Phosphate
- Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05510427Written as Infigratinib
- A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaTerminatedPhase 2QED Therapeutics, Inc.NCT02150967Written as BGJ398 (infigratinib)
- Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 AlterationsWithdrawnPhase 1/2Helsinn Healthcare SANCT05222165Written as Infigratinib
- Phase I BLASST-3 TrialWithdrawnPhase 1Guru P. SonpavdeNCT04972253Written as Infigratinib
- Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownPhase 2LianBio LLCNCT05019794Written as Infigratinib
Codes
What other systems call infigratinib · ClinicalTrials.gg INT005959
- MeSH (NLM) C568950infigratinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) A4055ME1VKINFIGRATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2550729One source FDA
- Wikidata Q27075200infigratinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88302InfigratinibOne source FDA
- DrugBank DB11886One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C568950 | infigratinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | A4055ME1VK | INFIGRATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2550729 | — | One source FDA |
| Wikidata | Q27075200 | infigratinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88302 | Infigratinib | One source FDA |
| DrugBank | DB11886 | — | One source Wikidata |
Also registered as infigratinib phosphate (UNII 58BH47BV6S).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.